Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISH 2022 | Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALL

Naoki Hosen • 8 Oct 2022
ISH 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Naoki Hosen, PhD, Osaka University Graduate School of Medicine, Osaka, Japan, comments on the use of inotuzumab ozogamicin and blinatumomab prior to and after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). This interview took place at the 38th World Congress of the International Society of Hematology 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naoki Hosen

0:47
Novel targets in CAR-T therapy for multiple myeloma: integrin beta-7 & CD98 heavy chain
Naoki Hosen • 8 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals